Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Noh MY, Cho KA, Kim H, Kim SM, Kim SH.

Neurosci Lett. 2014 Jun 27;574:53-8. doi: 10.1016/j.neulet.2014.05.001. Epub 2014 May 10.

PMID:
24820540
2.
3.

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, Hensley K, Beal MF, Kiaei M.

Exp Neurol. 2009 Nov;220(1):191-7. doi: 10.1016/j.expneurol.2009.08.028. Epub 2009 Sep 4.

4.

Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K.

J Neurochem. 2002 Jul;82(2):365-74. Erratum in: J Neurochem 2002 Sep;82(6):1570.

5.

Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis.

Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF.

Neurodegener Dis. 2005;2(5):246-54.

PMID:
16909005
6.

Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.

Tanaka K, Kanno T, Yanagisawa Y, Yasutake K, Hadano S, Yoshii F, Ikeda JE.

Exp Neurol. 2011 Nov;232(1):41-52. doi: 10.1016/j.expneurol.2011.08.001. Epub 2011 Aug 16.

PMID:
21867702
7.

Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.

Ahn SW, Jeon GS, Kim MJ, Shon JH, Kim JE, Shin JY, Kim SM, Kim SH, Ye IH, Lee KW, Hong YH, Sung JJ.

J Neurol Sci. 2014 May 15;340(1-2):112-6. doi: 10.1016/j.jns.2014.03.008. Epub 2014 Mar 12.

PMID:
24680562
8.

Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Milanese M, Giribaldi F, Melone M, Bonifacino T, Musante I, Carminati E, Rossi PI, Vergani L, Voci A, Conti F, Puliti A, Bonanno G.

Neurobiol Dis. 2014 Apr;64:48-59. doi: 10.1016/j.nbd.2013.11.006. Epub 2013 Dec 19.

9.

Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.

Han Y, Ripley B, Serada S, Naka T, Fujimoto M.

PLoS One. 2016 Apr 12;11(4):e0153399. doi: 10.1371/journal.pone.0153399. eCollection 2016.

10.

Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF.

J Neurosci. 2006 Mar 1;26(9):2467-73.

11.

Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.

Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, Kim SH.

Exp Neurol. 2007 Jun;205(2):336-46. Epub 2007 Mar 12.

PMID:
17433298
12.

Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.

Apolloni S, Amadio S, Montilli C, Volonté C, D'Ambrosi N.

Hum Mol Genet. 2013 Oct 15;22(20):4102-16. doi: 10.1093/hmg/ddt259. Epub 2013 Jun 4.

PMID:
23736299
13.

Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.

Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, Kobayashi M.

Neuropathology. 2008 Aug;28(4):387-98. doi: 10.1111/j.1440-1789.2008.00890.x. Epub 2008 Feb 26.

PMID:
18312546
14.

The anti-inflammatory peptide stearyl-norleucine-VIP delays disease onset and extends survival in a rat model of inherited amyotrophic lateral sclerosis.

Goursaud S, Schäfer S, Dumont AO, Vergouts M, Gallo A, Desmet N, Deumens R, Hermans E.

Exp Neurol. 2015 Jan;263:91-101. doi: 10.1016/j.expneurol.2014.09.022. Epub 2014 Oct 13.

PMID:
25311268
15.

Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis.

Kim J, Kim TY, Cho KS, Kim HN, Koh JY.

Neurobiol Dis. 2013 Nov;59:80-5. doi: 10.1016/j.nbd.2013.07.011. Epub 2013 Jul 26.

PMID:
23891729
16.

Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.

Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, Salmona M, Collina S, Bigini P, Curti D.

Neurobiol Dis. 2014 Feb;62:218-32. doi: 10.1016/j.nbd.2013.10.010. Epub 2013 Oct 16.

PMID:
24141020
17.

Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.

Apolloni S, Fabbrizio P, Parisi C, Amadio S, Volonté C.

Mol Neurobiol. 2016 Jan;53(1):518-531. doi: 10.1007/s12035-014-9019-8. Epub 2014 Dec 9.

PMID:
25482048
18.

Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.

Jeon GS, Im W, Shim YM, Lee M, Kim MJ, Hong YH, Seong SY, Kim M, Sung JJ.

Neurochem Res. 2016 Apr;41(4):913-23. doi: 10.1007/s11064-015-1774-z. Epub 2015 Dec 8.

PMID:
26646002
19.

Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis.

Elliott JL.

Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):172-8.

PMID:
11687290
20.

PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Ringer C, Büning LS, Schäfer MK, Eiden LE, Weihe E, Schütz B.

Neurobiol Dis. 2013 Jun;54:32-42. doi: 10.1016/j.nbd.2013.02.010. Epub 2013 Mar 4.

Supplemental Content

Support Center